AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
AnaptysBio news
05.05.2022
AnaptysBio's GAAP loss for 3 months of 2022 was $36.255 million, up 99.6% from $18.163 million in the prior year. Revenue decreased 11.59 times to $0.97 million from $11.247 million a year earlier.
Source: 
ir.anaptysbio.com
ir.anaptysbio.com
07.03.2022
AnaptysBio's GAAP loss for 2021 was $57.796 million, up 2.9 times from $19.931 million in the previous year. Revenue decreased 15.8% to $63.175 million from $75 million a year earlier.
Source: ir.anaptysbio.com
ir.anaptysbio.com
05.11.2021
AnaptysBio's GAAP loss for 9M 2021 was $25.258 million, down 2.2 times from $53.577 million in the previous year. Revenue increased 4.1 times to $62.164 million from $15 million a year earlier.
Source: ir.anaptysbio.com
ir.anaptysbio.com
10.08.2021
AnaptysBio's GAAP loss for 6M 2021 was $18.592 million, down 37.6% from $29.81 million in the previous year. Revenue increased 2.8 times to $41.274 million from $15 million a year earlier.
Source: ir.anaptysbio.com
ir.anaptysbio.com
General information
| Company name | AnaptysBio |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 10421 PACIFIC CENTER COURT, SUITE 200 SAN DIEGO CA 92121 858-362-6295 |
| Mailing address | 10421 PACIFIC CENTER COURT, SUITE 200 SAN DIEGO CA 92121 |
| Website | www.anaptysbio.com |
| Information disclosure | www.sec.gov |
English (US) 